BYFAVO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BYFAVO (BYFAVO).
Selective adenosine A2A receptor antagonist; promotes wakefulness by blocking the inhibitory effects of adenosine on arousal-promoting neurons in the brain.
| Metabolism | Primarily metabolized by CYP3A4 and CYP2D6, with minor contribution from CYP1A2. |
| Excretion | Renal excretion accounts for approximately 90% of the administered dose, with <5% as unchanged drug. Biliary/fecal elimination is minimal (<5%). |
| Half-life | Terminal elimination half-life is approximately 2-4 hours; clinical context: requires continuous infusion for sustained effect, as rapid clearance may lead to loss of efficacy. |
| Protein binding | Approximately 70-80% bound to human serum albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution (Vd) is 0.3-0.5 L/kg; clinical meaning: indicates moderate distribution into tissues, not extensive peripheral sequestration. |
| Bioavailability | Bioavailability is not applicable for intravenous formulation; oral bioavailability is negligible due to extensive first-pass metabolism (<5% if administered orally). |
| Onset of Action | Intravenous: Onset of sedation/hypnosis occurs within 1-2 minutes after bolus administration. |
| Duration of Action | Duration of sedation is short, typically 5-10 minutes after a single bolus dose; clinical note: titratable for procedural sedation, requires repeated dosing or infusion for prolonged procedures. |
| Molecular Weight | 250.25 |
For induction and maintenance of general anesthesia: 0.3 mg/kg intravenously over 30 seconds, followed by an infusion of 1.5 mg/kg/hour adjusted to effect. Additional boluses of 0.075 mg/kg may be given as needed.
| Dosage form | POWDER |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (eGFR <30 mL/min/1.73 m²), consider reduced infusion rate due to prolonged recovery times; specific dose not established. |
| Liver impairment | Child-Pugh A and B: No adjustment. Child-Pugh C: Reduce infusion rate by 50% and monitor for prolonged sedation; starting infusion at 0.75 mg/kg/hour is recommended. |
| Pediatric use | Not approved for pediatric patients <18 years of age. Safety and efficacy not established. |
| Geriatric use | For patients ≥65 years, consider lower initial infusion rate (1 mg/kg/hour) and reduce bolus doses; titrate carefully due to increased sensitivity and slower emergence from anesthesia. |
| 1st trimester | Avoid: Risk of teratogenicity (neural tube defects, cardiovascular malformations). Case reports of fetal malformations with first-trimester exposure. |
| 2nd trimester | Caution: Limited data; potential for fetal renal impairment and oligohydramnios with prolonged use. |
| 3rd trimester | Caution: Risk of neonatal hypoglycemia, hyperbilirubinemia, and hemolytic anemia. Avoid near term due to possible kernicterus. |
Clinical note
Comprehensive clinical and safety monograph for BYFAVO (BYFAVO).
| Placental transfer | Crosses placenta; fetal levels reach 50-100% of maternal serum concentrations. |
| Breastfeeding | Enters breast milk in low concentrations. Monitor infant for rash, diarrhea, and jaundice. Consider alternative agent if infant has G6PD deficiency or hyperbilirubinemia. |
■ FDA Black Box Warning
Not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C).
| Serious Effects |
Hypersensitivity to sulfonamides or any componentSevere hepatic impairmentPorphyriaG6PD deficiency (relative, consider risk)Pregnancy (first trimester)
| Precautions | Risk of transient ischemic attacks and seizures; discontinue use if neurological symptoms occur., May cause dose-related increases in blood pressure and heart rate; monitor cardiovascular status., Not recommended in patients with unstable cardiovascular disease, recent myocardial infarction, or stroke., Potential for drug interactions with strong CYP3A4 inhibitors or inducers., May cause insomnia, anxiety, or restlessness. |
| Food/Dietary | No specific food interactions are reported. However, because sedation may cause nausea, avoid heavy meals immediately before sedation. Grapefruit juice does not significantly interact with remimazolam. |
Loading safety data…
| Lactation Rating |
| L3 (Moderately Safe) |
| Teratogenic Risk | BYFAVO is contraindicated in pregnancy. Animal studies show teratogenicity and embryotoxicity in first trimester. Human data insufficient; risk cannot be excluded in all trimesters. Effective contraception required. |
| Fetal Monitoring | Monitor liver function tests, complete blood count, and renal function periodically. In pregnant patients, if exposure occurs, perform ultrasound for fetal development. |
| Fertility Effects | Based on animal studies, BYFAVO may impair female fertility. No data on male fertility. Women of childbearing potential should be advised of potential risk. |
| Clinical Pearls | BYFAVO (remimazolam) is an ultra-short-acting benzodiazepine for procedural sedation. Onset within 1-2 minutes, recovery typically within 10 minutes. Flumazenil is the reversal agent. Monitor for respiratory depression; have resuscitation equipment available. Avoid in severe hepatic impairment. Coadministration with opioids increases sedation depth; reduce doses accordingly. |
| Patient Advice | You will be closely monitored during the procedure. Do not drive, operate machinery, or make important decisions for at least 24 hours after receiving this medication. · Inform your healthcare provider if you have a history of liver disease, glaucoma, or substance abuse. · Do not consume alcohol for at least 24 hours after sedation. · You may experience temporary memory loss or drowsiness; arrange for a responsible adult to accompany you home. · Report any unusual side effects such as prolonged drowsiness, difficulty breathing, or allergic reactions (rash, swelling) to your doctor immediately. |